Our archers pick up their bows and arrows and take aim at this week’s stories. Only on the PlayingFTSE show!

Steve and Steve are in this week to talk about stories. And they’re starting with the small stuff. It’s the UK’s latest economic plan.

This has been top of mind for Steve W for a few days now and he’s been trying to figure his way around it. He’s not a fan, but he thinks it’s been badly covered in the mainstream media. What does it mean for the Steves and UK citizens and UK investors? Neither has an answer, but they’ll do their best to try and work through things.

It’s unusual that we get ourselves involved in anything political and so the rest of the show is stocks, stocks, and more stocks. We’ve got SIX that are on our radar as we head into October and Q4.

First up, Steve D is looking at Kering. He’s nearly always looking at Kering, because of all the designer gear he frequently wears. But he thinks the shares are particularly eye-catching at the moment. Find out why as Steve takes us through the stock’s latest decline.

Second, Steve W is looking at Rightmove. He’s nearly always looking at Rightmove, because of his enormous property empire. But he thinks that the shares are particularly eye-catching at the moment. Find out why as Steve takes us through the stock’s latest decline.

Third, Steve D is watching Legal & General. The UK insurer stands to do well as interest rates rise and the stock has come down to a level where Steve thinks it pays an interesting dividend. Could this be enough to get him over the line?

Fourth, Steve W is watching Wells Fargo. The US bank stands to do well as interest rates rise and the stock has come down to a level where Steve thinks it pays an interesting dividend. Could this be enough to get him over the line?

Fifth, Steve D has his eye on some healthcare. This is one we haven’t talked about much on the show, but Steve is looking at Biomerieux. Steve doesn’t back himself to evaluate a pharmaceutical’s pipeline, but his thesis here doesn’t depend on this. So what’s he seeing here?

Sixth, Steve W has his eye on some healthcare. This is one we haven’t talked about much on the show, but Steve is looking at GSK. Steve doesn’t back himself to evaluate a pharmaceutical’s pipeline, but his thesis doesn’t depend on this. So what’s he seeing here?

All on this week's PlayingFTSE Podcast!